Work

Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)

Year: 2020

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2020-ct201

Authors: Byoung Chul Cho, Nathan Bahary, Johanna Bendell, Enriqueta Felip, Melissa Johnson, Yoon-Koo Kang, Farah Louise Lim, Teresa Macarulla, Gulam Manji, Do-Youn Oh, Osama Rahma, Simon Allen, Edward Cha, Denise Cotting, Hans-Joachim Helms, Jan Pintoffl, Pakeeza Sayyed, Xiaosong Zhang, Kyu-pyo Kim

Institutions: Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, University of Pittsburgh Medical Center, Sarah Cannon, Tennessee Oncology, Vall d'Hebron Institute of Oncology, Asan Medical Center, University of Ulsan, Queen Mary University of London, Barts Cancer Institute, Columbia University Irving Medical Center, Seoul National University, Dana-Farber Cancer Institute, Annexon Biosciences (United States), Instacart (United States), F. Hoffmann-La Roche AG

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3083183252

Cites:

Cited by: 4

Related to: 10